NCT00279435View on ClinicalTrials.gov

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions

Ulcerative Colitis

Interventions

DRUG

visilizumab

Trial Locations (39)

1105

Amsterdam

2170

Liverpool

3000

Leuven

3128

Box Hill

6160

Fremantle

10029

New York

15261

Pittsburgh

17033

Hershey

30342

Atlanta

31000

Osijek

40138

Bologna

40202

Louisville

52621

Tel Litwinsky

59037

Lille

65025

Odesa

75010

Paris

84107

Murray

92110

Clichy

02118

Boston

01655

Worcester

37232-2285

Nashville

QLD 4029

Herston

A-1090

Vienna

B-9000

Ghent

R3A 1R9

Winnipeg

L8N 3Z5

Hamilton

T2N 4N1

Calgary

HR-10000

Zagreb

Unknown

Brno

Szekszárd

Oslo

Tromsø

120 00

Prague

D-13353

Berlin

D-79106

Freiburg im Breisgau

D-24105

Kiel

H-3501

Csabai Kapu

H-9024

Vasvári Pál

H-2601

Vác

Sponsors

Lead Sponsor

Collaborators (1)

PDL BioPharma, Inc.

All Listed Sponsors

collaborator

PDL BioPharma, Inc.

INDUSTRY

lead

Facet Biotech

INDUSTRY

NCT00279435 - Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study | Biotech Hunter | Biotech Hunter